TY - JOUR
T1 - Missing heritability in Parkinson’s disease
T2 - the emerging role of non-coding genetic variation
AU - Ohnmacht, Jochen
AU - May, Patrick
AU - Sinkkonen, Lasse
AU - Krüger, Rejko
N1 - Funding Information:
This work was supported by grants from the Luxembourg National Research Fund (FNR) for the National Centre for Excellence in Research on Parkinson’s disease (NCER-PD to RK, PM), the PEARL program (FNR/P13/6682797 to RK), MotaSYN (12719684 to RK), MAMaSyn (to RK) and MiRisk‐PD (C17/BM/11676395 to RK and PM). JO is supported by a postdoctoral fellowship from the Fondation du Pélican de Mie et Pierre Hippert-Faber and has received a research grant from Luxembourg Rotary Foundation. RK has received research grants from the Michael J Fox Foundation, the European Union’s Joint Program-Neurodegenerative Diseases (JPND; COURAGE-PD), the European Union’s Horizon2020 research and innovation program (No 692320), and the Federal Ministry for Education and Research (BMBF; Mito-PD 031 A 430 A), as well as funding by the Fonds Amélie and Hélène de Fabribeckers, the Fondation Roi Baudouin, Claudie Stein-Lambert as well as by other private donors. LS has received funding from Fonds National de Recherche de Luxembourg (FNR) within CORE project DANeuroGen (C15/BM/10406131) and has received research grants from Fonds National de Recherche de Luxembourg (FNR), Fondation du Pélican de Mie et Pierre Hippert-Faber, Luxembourg Rotary Foundation, Luxembourg Personalized Medicine Consortium, and University of Luxembourg Internal Research Project grants.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Parkinson’s disease (PD) is a neurodegenerative disorder caused by a complex interplay of genetic and environmental factors. For the stratification of PD patients and the development of advanced clinical trials, including causative treatments, a better understanding of the underlying genetic architecture of PD is required. Despite substantial efforts, genome-wide association studies have not been able to explain most of the observed heritability. The majority of PD-associated genetic variants are located in non-coding regions of the genome. A systematic assessment of their functional role is hampered by our incomplete understanding of genotype–phenotype correlations, for example through differential regulation of gene expression. Here, the recent progress and remaining challenges for the elucidation of the role of non-coding genetic variants is reviewed with a focus on PD as a complex disease with multifactorial origins. The function of gene regulatory elements and the impact of non-coding variants on them, and the means to map these elements on a genome-wide level, will be delineated. Moreover, examples of how the integration of functional genomic annotations can serve to identify disease-associated pathways and to prioritize disease- and cell type-specific regulatory variants will be given. Finally, strategies for functional validation and considerations for suitable model systems are outlined. Together this emphasizes the contribution of rare and common genetic variants to the complex pathogenesis of PD and points to remaining challenges for the dissection of genetic complexity that may allow for better stratification, improved diagnostics and more targeted treatments for PD in the future.
AB - Parkinson’s disease (PD) is a neurodegenerative disorder caused by a complex interplay of genetic and environmental factors. For the stratification of PD patients and the development of advanced clinical trials, including causative treatments, a better understanding of the underlying genetic architecture of PD is required. Despite substantial efforts, genome-wide association studies have not been able to explain most of the observed heritability. The majority of PD-associated genetic variants are located in non-coding regions of the genome. A systematic assessment of their functional role is hampered by our incomplete understanding of genotype–phenotype correlations, for example through differential regulation of gene expression. Here, the recent progress and remaining challenges for the elucidation of the role of non-coding genetic variants is reviewed with a focus on PD as a complex disease with multifactorial origins. The function of gene regulatory elements and the impact of non-coding variants on them, and the means to map these elements on a genome-wide level, will be delineated. Moreover, examples of how the integration of functional genomic annotations can serve to identify disease-associated pathways and to prioritize disease- and cell type-specific regulatory variants will be given. Finally, strategies for functional validation and considerations for suitable model systems are outlined. Together this emphasizes the contribution of rare and common genetic variants to the complex pathogenesis of PD and points to remaining challenges for the dissection of genetic complexity that may allow for better stratification, improved diagnostics and more targeted treatments for PD in the future.
KW - Gene regulation
KW - Genetic modifier
KW - Genetic susceptibility
KW - Genome-wide association studies
KW - Non-coding variation
KW - Parkinson’s disease
KW - Polygenic risk scores
UR - http://www.scopus.com/inward/record.url?scp=85082955024&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/32248367
U2 - 10.1007/s00702-020-02184-0
DO - 10.1007/s00702-020-02184-0
M3 - Review article
C2 - 32248367
AN - SCOPUS:85082955024
SN - 0300-9564
VL - 127
SP - 729
EP - 748
JO - Journal of Neural Transmission
JF - Journal of Neural Transmission
IS - 5
ER -